Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12130576 | 0.81 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4853754 | 0.79 | CHRNB4 (0.36) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8092365 | 0.78 | LTA4H (0.37) | SLC6A2SLC6A4 | |
| SCHEMBL1282981 | 0.77 | CHRNB4 (0.34) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL12130449 | 0.74 | HRH3 (0.43) | SLC6A3SLC6A2SLC6A4GRIN1GRIN2A | |
| SCHEMBL12130554 | 0.74 | HRH3 (0.43) | SLC6A3SLC6A2SLC6A4GRIN1GRIN2A | |
| SCHEMBL5273491 | 0.73 | MCHR1 (0.36) | — | |
| SCHEMBL12130553 | 0.73 | SLC6A2 (0.42) | SLC6A3SLC6A2SLC6A4GRIN1GRIN2A | |
| SCHEMBL12130611 | 0.71 | LTA4H (0.47) | SLC6A3SLC6A2SLC6A4GRIN1GRIN2A | |
| SCHEMBL4498294 | 0.71 | SLC6A3 (0.34) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053247-A1 | ANTIFUNGAL CYCLOHEXAPEPTIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040108-A1 | NEW COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-12 | — | — | WO | disclosed |